This Australia state and territory atlas resolves DSIP / Emideltide to its fda-flagged unapproved research-market peptide identity first, then connects that identity to eight official local pharmacy or medicines routes, the ARTG, and the national practitioner register. It answers where to check a product, sponsor, pharmacy, premises, practitioner, or seller claim without turning a shared name, research listing, clinical program, local record, or national record into a blanket legal, availability, quality, safety, or medical conclusion.
DSIP, also called emideltide or delta sleep-inducing peptide, is tracked here as a US research-market identity. FDA has identified emideltide among bulk substances that may present significant safety risks in compounding and notes important gaps in human safety information. That does not establish an approved medicine, a lawful local supply route, seller identity, product quality, or suitability for use in any destination.
Primary identity source: Read the FDA source / U.S. Food and Drug Administration ↗These answers define what a compound identity, ARTG record, practitioner record, and state or territory route can establish. They are not medical advice, legal advice, seller certification, or an availability finding.
No blanket answer is supportable. Product identity, ARTG inclusion, prescription requirements, compounding, practitioner registration, pharmacy or premises authority, import conditions, advertising, and the actual supply route are separate questions. Choose the destination below and verify the exact current records before treating an offer as authorized or available.
No. A state or territory record can help resolve the pharmacy, premises, licence, or supply category behind a claim, but it does not prove that the pictured vial, ingredient, presentation, sponsor, batch, prescription route, compounding basis, import route, or delivery claim matches an ARTG entry or lawful transaction.
Resolve the compound through its primary identity source, search the exact therapeutic good and sponsor in the ARTG, verify the practitioner in Ahpra when relevant, open the destination jurisdiction's official route, and compare only offers with the same category, presentation, supply route, evidence access, total price, and observation date.
The sequence stays fixed while the jurisdiction regulator, pharmacy or premises identity, product record, and claimed supply route change.
Open the primary identity record and preserve its research-market, clinical-pipeline, or medicine evidence lane.
Search the exact product and sponsor in the ARTG, then verify the practitioner separately when the offer depends on professional care.
Match the pharmacy, premises, licence, registration, or medicines-supply claim in the destination state or territory.
Each card joins the resolved compound identity to the ARTG, one official local route, and a substantive regional guide with a capital-city handoff.
DSIP / Emideltide in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.
DSIP / Emideltide in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.
DSIP / Emideltide in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.
DSIP / Emideltide in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.
DSIP / Emideltide in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.
DSIP / Emideltide in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.
DSIP / Emideltide in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.
DSIP / Emideltide in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.
Use the atlas for a readable Australian comparison or download the complete dataset. Every record retains the identity source, ARTG route, jurisdiction route, review date, and canonical section link.
Download all 328 compound-jurisdiction rows →Compare DSIP / Emideltide across 42 countries →Open the Australia country guide →Browse every country, province, state, region, and city guide →Read the publication standard →